Effects of colestipol, clofibrate, and placebo on plasma lipoproteins of patients with hypercholesterolemia.
Effects of colestipol, clofibrate, and placebo on plasma lipoproteins of patients with hypercholesterolemia.
复制标题
考来替泊、氯贝丁酯和安慰剂对高胆固醇血症患者血浆脂蛋白的影响。
DOI：
10.1016/0026-0495(81)90160-8
复制
发表时间：
1981
期刊：
影响因子：
--
通讯作者：
Grundy,SM
中科院分区：
文献类型：
--
作者：
Crouse,JR;Grundy,SM
为了评估colestipol和clofibrate对高胆固醇血症和甘油三酯浓度正常患者的疗效，27例患者随机分为三组，colestipol、clofibrate、在超过8个月的单盲方案中，比较了阿维索粉和安慰剂对总血脂、脂蛋白胆固醇和甘油三酯浓度的影响。低密度脂蛋白(LDL)-胆固醇和极低密度脂蛋白（VLDL）甘油三酯的平均预处理值分别为250 mg/dl和68 mg/dl。Colestipol （30 g/天）使总胆固醇和低密度脂蛋白胆固醇分别降低25%和31%，而vldl -甘油三酯升高。总的来说，氯贝特降低了总胆固醇和低密度脂蛋白胆固醇13%和12%，降低了低密度脂蛋白甘油三酯21%和低密度脂蛋白胆固醇50%。对于氯贝特，某些患者表现出比其他患者更明显的效果：在9名患者中，7名患者的平均总胆固醇和低密度脂蛋白胆固醇分别降低了17%（范围为8% - 31%）和19%（范围为10%-44%），而2名患者对氯贝特没有反应。这些患者的高密度脂蛋白不受colestipol或clofibrate的影响。因此，虽然colestipol更有效，但某些高胆固醇血症患者对clofibrate的反应同样好，总胆固醇、低密度脂蛋白胆固醇和低密度脂蛋白胆固醇均显著降低。
To evaluate the effectiveness of colestipol and clofibrate in patients with hypercholesterolemia and normal concentrations of triglycerides, 27 patients were randomized into three groups, and colestipol, clofibrate, and avicel powder placebo were compared for effects on concentration of total plasma lipid and lipoprotein cholesterol and triglyceride in a single blind protocol over 8 mo. Mean pretreatment values for low density lipoprotein (LDL)-cholesterol and very low density lipoprotein (VLDL) triglyceride were 250 mg/dl and 68 mg/dl, respectively. Colestipol (30 g/day) lowered total- and LDL-cholesterol by 25% and 31%, respectively, while VLDL-triglyceride rose. Overall clofibrate lowered total- and LDL-cholesterol by 13% and 12% while lowering VLDL-triglyceride 21% and VLDL cholesterol by 50%. For clofibrate, certain patients showed a more pronounced effect than others: in seven of nine patients clofibrate lowered both mean total- and LDL-cholesterol by 17% (range 8% to 31%) and 19% (range 10%–44%) respectively, whereas two patients did not respond to clofibrate. High density lipoproteins were not affected by either colestipol or clofibrate in these patients. Thus, while colestipol was more consistently effective, certain hypercholesterolemic patients responded equally well to clofibrate with substantial lowering of total-, LDL-, and VLDL-cholesterol.